Aromatase Inhibitor News and Research

RSS

Aromatase Inhibitors are drugs that prevent the formation of estradiol, a female hormone, by interfering with an aromatase enzyme. Aromatase inhibitors are used as a type of hormone therapy for postmenopausal women who have hormone-dependent breast cancer.

Latest drugs improve survival for metastatic breast cancer

Newer drug therapies available since the 1990s, in particular aromatase inhibitors, improve the survival of women with metastatic breast cancer in the general population, according to a new study.

23 Jul 2007

Group therapy does not prolong the lives of women with metastatic breast cancer

Earlier results from the same researcher had suggested a survival benefit of group therapy for women with metastatic breast cancer. However, the new study did find that women with estrogen receptor (ER) negative tumors did show survival benefit, and that group therapy improved quality of life (QOL).

23 Jul 2007

Women well-informed about breast cancer although lack knowledge about current treatments

According to a new GfK Roper Public Affairs survey sponsored by CancerCare, a national nonprofit cancer support organization, while the majority (76 percent) of women surveyed said they know at least a fair amount about breast cancer, many remain unaware of the important recent progress made in treatment.

16 Jun 2007

Depression is a risk factor for osteoporosis

Evidence is accumulating that depression is a risk factor for osteoporosis, reports the June 2007 issue of Harvard Women's Health Watch.

30 May 2007

Women with breast cancer do not get potentially life-saving information

New published data from a large pan-European survey indicate that the majority of postmenopausal women with early breast cancer taking post-surgical endocrine therapy are not involved in making key decisions about their treatment, nor are they given sufficient information to make informed treatment choices that could affect their long-term outcome.

28 May 2007

Hospital-based performance measures for quality of care for breast and colorectal cancer

In a move more than two years in the making, a National Quality Forum (NQF) endorsement became effective today of the first nationally recognized hospital-based performance measures for quality of care for breast and colorectal cancer.

15 Apr 2007

Switching treatment to exemestane after 2-3 years on tamoxifen, improves survival

The Intergroup Exemestane Study (IES), an extensive, international study, tested the superiority of switching to exemestane (an aromatase inhibitor) from tamoxifen in patients with early breast cancer.

13 Feb 2007

Breast cancer survival rates improved by novel drug sequence

Changing the way women are treated for breast cancer could improve their overall chance of survival, according to research published in the Lancet.

13 Feb 2007

Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma

For breast cancer patients taking tamoxifen, switching to an aromatase inhibitor within three years significantly improves survival rates, according to a new study.

12 Feb 2007

Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women

Aromatase inhibitors, a type of hormone therapy used to treat advanced breast cancer in postmenopausal women, result in a small but significant increase in overall survival when compared to other hormone treatments, according to a new systematic review of studies.

30 Jan 2007

Scientists discover how androgen plays a role in the development of prostate cancer

Scientists have discovered for the first time a specific biochemical pathway by which the sex hormone, androgen, increases levels of harmful chemicals called reactive oxygen species (ROS) in the prostate gland that play a role in the development of prostate cancer.

8 Nov 2006

Identifying breast cancer patients most likely to benefit from Aromatase Inhibitor Therapy after adjuvant radiation and Tamoxifen

While some breast cancer survivors could benefit from adding aromatase inhibitors to the standard five years of tamoxifen, a new study shows the additional therapy should be weighed carefully for each individual.

23 Oct 2006

Aromatase inhibitors improve survival of advanced breast cancer patients compared to tamoxifen

Aromatase inhibitors improve the survival of advanced breast cancer patients compared to standard hormone therapies like tamoxifen, a researchers report in the September 20 issue of the Journal of the National Cancer Institute.

19 Sep 2006

Basal tumours may originate from breast stem cells that have undergone genetic mishaps

Findings support previous speculation that breast stem cells, or very early descendents, are the cells from which basal tumours arise.

24 Jul 2006

Combination of anastrozole and a synthetic hormone called goserelin may slow male breast cancer growth

Medical oncologists across the nation want to know whether a certain drug combination can slow the progression of male breast cancer, a rare disease that often goes undiagnosed until it's in an advanced stage.

10 Jul 2006

Hormonal treatments reduce risk of cancer returning

Women diagnosed with breast cancer who carry a certain genetic mutation can have breast-sparing surgery but should consider hormonal treatments to reduce their risk of cancer returning.

6 Jun 2006

Nimesulide fights breast cancer by targeting key enzyme

A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.

16 Apr 2006

Researchers show how estrogen turns genes on and off during cancer progression

Ohio - A new study suggests that the hormone estrogen works in partnership with other proteins to activate or suppress gene activity in breast cancer cells.

2 Feb 2006

Warning of risk of from vaginal oestrogen

Breast cancer specialists from one of the UK's leading cancer centres cautioned doctors of the risks in prescribing vaginal oestrogen to breast cancer patients being treated with the new aromatase inhibiting drugs, anastrozole, letrozole and exemestane.

26 Jan 2006

New breast cancer drug Femara will save lives

Following the results of a worldwide study, U.S. regulators have given approval for the use of the drug Femara for women with early breast cancer directly after they have had surgery.

29 Dec 2005